Oral arsenic therapy for TP53-mutated blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of oral medications, including arsenic trioxide, venetoclax, and a chemotherapy agent (azacitidine or decitabine), for people with certain blood cancers (AML, MDS, or CMML) that have a TP53 gene mutation. The goal is to see if this pill-based treatment can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).
- Your cancer must have a TP53 gene mutation (a change in a specific gene).
- If you have not had any prior treatment, you can join one group (Cohort A). If you have had one or more prior treatments that stopped working, you can join another group (Cohort B).
- You must be well enough to perform daily activities (ECOG score 0 to 2).
- You must agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding arsenic trioxide (a drug) to the standard transplant process can lower the risk of leukemia coming back. It is for people with AML or MDS who have a certain genetic change (TP53 mutation) and are about to have their first stem cell transplant from a matched donor.
This trial tests a new combination of drugs (axatilimab, decitabine, and venetoclax) for people with a specific type of acute myeloid leukemia (AML) that has a change in the TP53 gene. The goal is to see if this treatment can help when standard treatments haven't worked or for newly diagnosed patients with this genetic change.
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
This study tests whether combining a new drug called ATRN-119 with a cancer medicine called decitabine can help patients with acute myeloid leukemia (AML) or a related bone marrow condition called high-risk myelodysplastic syndrome (MDS), especially those whose cancer cells have changes in a gene called TP53. The trial is looking for patients who have not responded to or cannot tolerate standard treatments.
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
This Phase 2 study tests an oral form of arsenic trioxide in people newly diagnosed with APL (a specific leukemia subtype). It aims to see how well this frontline treatment works and whether it can be given safely.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.